Welcome to our dedicated page for Xilio Therapeutics news (Ticker: XLO), a resource for investors and traders seeking the latest updates and insights on Xilio Therapeutics stock.
Xilio Therapeutics, Inc. (XLO) is a clinical-stage biotechnology company pioneering tumor-activated therapies designed to target cancer precisely while reducing systemic side effects. This page serves as the definitive source for verified news and press releases related to XLO’s innovative immuno-oncology pipeline and strategic developments.
Investors and industry professionals will find timely updates on clinical trial progress, regulatory milestones, and research partnerships. Our curated collection includes announcements about XLO’s proprietary platform, engineered therapies (including cytokines, antibodies, and bispecifics), and collaborations advancing targeted cancer treatments.
Key updates cover advancements in tumor-activated IL-12, CTLA-4 inhibitors, and T cell engagers – all leveraging XLO’s focus on activating therapies exclusively within the tumor microenvironment. Bookmark this page to stay informed about developments that highlight the company’s scientific rigor and position in the competitive biotech landscape.
Xilio Therapeutics (NASDAQ:XLO) reported Q2 2025 financial results and pipeline updates. The company's lead candidate vilastobart showed promising Phase 2 data with a 26% objective response rate in metastatic MSS colorectal cancer patients without liver metastases. The therapy demonstrated deep, durable responses and a differentiated safety profile.
Financial highlights include $121.6 million in cash and cash equivalents, a net loss of $15.8 million, and revenue of $8.1 million. The company completed a follow-on offering raising $50.0 million in initial gross proceeds, with potential for additional $100.0 million from warrant exercises.
Xilio expects to nominate development candidates for its masked T cell engager programs in H2 2025 and projects cash runway through Q3 2026.
Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has granted inducement stock options to two new employees. The grants include options to purchase 134,000 shares of common stock at an exercise price of $0.65 per share, matching the closing price on August 1, 2025.
The stock options have a ten-year term with a vesting schedule of 25% after the first year and the remaining 75% vesting in 36 monthly installments. These grants were made under Xilio's 2022 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has granted stock options to two new employees effective July 1, 2025. The inducement grants include options to purchase 10,700 shares of common stock at an exercise price of $0.693 per share.
The stock options have a ten-year term with a vesting schedule of 25% after the first year and the remaining 75% vesting monthly over three years. These grants were made under Xilio's 2022 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
FAQ
What is the current stock price of Xilio Therapeutics (XLO)?
What is the market cap of Xilio Therapeutics (XLO)?
